Shanghai Biointron Biotech, an Upstream CRO for Antibody Discovery and Expression, Passes IPO Review on Beijing Stock Exchange
Biointron
CRO Service Provider
TJ Biopharma
Biopharmaceutical R&D and Manufacturer
Hengrui Pharma
Innovative and High-Quality Pharmaceutical Developer
AstraZeneca
Pharmaceutical Technology Research and Development Provider
Johnson & Johnson
Medical Device R&D and Manufacturer
With a perspective, with an attitude
This is the 1616-1st article of the Life Science Industry Observer WeChat Official Account.
On March 31, 2026, the Beijing Stock Exchange Listing Review Committee held the 34th review meeting of the Listing Review Committee in 2026. The review results showed,Taizhou Biointron Biological Inc. Meets the Requirements for Initial Public Offering, Listing Conditions, and Information Disclosure.
Public information shows,Taizhou Biointron Biological Inc. was founded in 2012 in Zhangjiang, Shanghai. It is a national high-tech enterprise and a national specialized and new "little giant" enterprise, focusing on antibody expression and antibody discovery and optimization CRO services.The company has provided pharmaceutical R&D outsourcing and other services to more than 2,500 pharmaceutical enterprises both in and outside China. Its main clients include many well-known domestic pharmaceutical companies such as TJ Biopharma, Harbour BioMed, Hengrui Pharma, Innovent Biologics, Lepu Biopharma, Henlius, CSPC Pharmaceutical Group, Changchun Jinshi, Hansoh Biopharma, as well as numerous internationally renowned pharmaceutical companies like AstraZeneca, Moderna, AbbVie, Bayer, and Johnson & Johnson.
The coaching filing report shows that Taizhou Biointron Biological Inc. submitted its initial public offering (IPO) application documents to the ChiNext Board of the Shenzhen Stock Exchange on June 25, 2023, which were accepted by the Shenzhen Stock Exchange on June 29, 2023. The company submitted a withdrawal application to the Shenzhen Stock Exchange on June 21, 2024.
Taizhou Biointron Biological Inc.'s revenue from 2022 to 2025 was 260 million yuan, 338 million yuan, 402 million yuan, and 247 million yuan, respectively; net profits were 57.6529 million yuan, 84.0211 million yuan, 124 million yuan, and 83.0009 million yuan, respectively.
Notably, as of February 2026, Taizhou Biointron Biological Inc. has completed three rounds of publicly disclosed market-based financing, with a total disclosed financing amount of approximately 610 million RMB. The specific details are as follows:
❖ Disclaimer: The content of this article is for learning and exchange purposes only. The views expressed are those of the author and do not necessarily represent those of the original author. For any questions, please contact the editor.
---The End---
Welcome to follow the official account.
If you like it, just one-click triple action: like, favorite, and share.！